Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

We are all familiar with DTC advertising campaigns for checkpoint inhibitors, which raise patient hopes and expectations for very expensive therapies that have very real toxicities. How do we apply lessons learned from previous experience to these newer agents?
JA14-Winship-at-the-Y
Beginning January 2022, CMS will be required to cover for Medicaid patients the routine costs associated with participating in clinical trials. Learn what states and provider organizations can do to leverage this mandate to address barriers to care in the community and reduce inequities in clinical trial participation.
The VCU Massey Cancer Center incorporated a legal service at their center because more work had to be done to address social determinants of health rooted in legal problems in order to offer comprehensive services that met the full gamut of its patients’ needs.
To adequately address patient financial toxicity, institutions must assume responsibility for ensuring that patients understand their insurance coverage and anticipated out-of-pocket expenses. Institutions should also have procedures in place to navigate the pre-certification process and prevent claim denials that may ultimately end up as the patient’s responsibility.
The practice of pharmacy, and in particular oncology pharmacy, has evolved through the years; it is no longer a discipline focused solely on drug therapy.
In August 2015 the Health Resources and Services Administration (HRSA) released its much-anticipated “mega-guidance” on the 340B Drug Pricing Program, proposing new limits on the program but stopping short of a complete overhaul, prompting mixed reviews from stakeholders.
MJ09-Tools-of-the-Trade
As the transition from the Enhancing Oncology Model to the Oncology Care Model beckons, cancer programs will need to be proactive as they undergo certain operational changes.
The COVID-19 virus entered our lives quickly, and almost no one could have predicted that several vaccines would be available less than a year after the public health emergency was declared. After the U.S. Food and Drug Administration issued the first emergency use authorization on Dec. 11, 2020, many Americans rushed to get in line for the first vaccine. While there was much concern …
ND13-The-NCCCP-Cancer-Genetic-Counseling-Assessment-Tool
A holistic Self-Care and Resiliency Program for Oncology Professionals has helped to decrease oncology staff burnout rates. Key components include Patient Remembrance Ceremonies, staff support groups, educational opportunities, and social events.
When SwedishAmerican Regional Cancer Center found itself unable to quantify performance in inpatient oncology, it saw an opportunity to break down barriers in communication and education between the inpatient and outpatient setting.
Although community-based psychological first aid training is most often provided to prepare for front-line emergencies, Avera Cancer Institute recognized the potential for this training to help foster a culture of resilience and mutual support.
JA12-The-Big-Picture
In 2016, Valley Health, a not-for-profit healthcare system serving patients in Maryland, Virginia, and West Virginia, partnered with a local dermatology office and various community and state stakeholders on a common goal to educate our community about smart sun protection decisions and the importance of skin cancer screenings.
Stony Brook Cancer Center staff and patients appreciate the bus service and what it entails: reduced travel time for patients, less fatigue for patients, a knowledgeable driver, and coordination with oncology services.
This tool is intended to help cancer programs create a high-quality, patient-focused process that provides a return on investment (ROI). The tool presents the infrastructure and the basic building blocks for starting a patient navigation program, as well as a framework for cancer programs to set goals and benchmarks and to grow their navigation services.
Biotechnology and Oncology: The Promise and the Challenges Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Biotechnology and Oncology: The Promise and the Challenges Dennis N. Longstreet …
ND07-Meeting-the-Challenge